OTC Markets OTCPK - Delayed Quote USD

Silence Therapeutics plc (SLNCF)

0.9700
0.0000
(0.00%)
At close: May 16 at 4:00:00 PM EDT
Loading Chart for SLNCF
  • Previous Close 0.0000
  • Open 0.8000
  • Bid 0.9700 x 40000
  • Ask 1.5900 x 40000
  • Day's Range 0.8000 - 0.9500
  • 52 Week Range 0.4986 - 14.7500
  • Volume 4,000
  • Avg. Volume 4,557
  • Market Cap (intraday) 137.44M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.5100
  • Earnings Date Aug 15, 2025 - Aug 29, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

www.silence-therapeutics.com

116

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SLNCF

View More

Performance Overview: SLNCF

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

SLNCF
63.05%
S&P 500 (^GSPC)
1.30%

1-Year Return

SLNCF
86.14%
S&P 500 (^GSPC)
12.48%

3-Year Return

SLNCF
85.63%
S&P 500 (^GSPC)
48.66%

5-Year Return

SLNCF
81.49%
S&P 500 (^GSPC)
108.07%

Compare To: SLNCF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SLNCF

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    137.44M

  • Enterprise Value

    966.12k

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    4.94

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    0.03

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    -0.5100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: SLNCF

View More

Company Insights: SLNCF

Research Reports: SLNCF

View More

People Also Watch